Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia - Summary - MDSpire

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

  • By

  • Thomas Roberts

  • Grace Uwenedi

  • Rachel Bruton

  • Graham McIlroy

  • Sarah Damery

  • Panagiota Sylla

  • Nicola Logan

  • Sam Scott

  • May Lau

  • Ahmed Elzaidi

  • Siobhan Plass

  • Soumyajit Mallick

  • Katie Spencer

  • Christine Stephens

  • Christopher Bentley

  • Guy Pratt

  • Jianmin Zuo

  • Shankara Paneesha

  • Brian Willett

  • Paul Moss

  • Helen Parry

  • January 25, 2024

  • 0 min

Share

Objective:

To evaluate the immune response to bivalent COVID-19 vaccines in patients with chronic lymphocytic leukaemia (CLL) compared to healthy controls.

Key Findings:
  • 87% of patients showed a measurable antibody response post-vaccination, comparable to 100% in healthy controls.
  • Antibody titres against both ancestral and Omicron spike proteins increased significantly after vaccination.
  • Cellular immunity showed a robust response, particularly against Omicron peptides, with a 3.1-fold increase.
Interpretation:

Bivalent vaccination enhances both humoral and cellular immune responses in CLL patients, particularly against the Omicron variant, although neutralization of recent subvariants remains limited, indicating a need for ongoing monitoring.

Limitations:
  • Small sample size of patients on BCL2 inhibitor therapy may limit generalizability.
  • Lack of neutralization data against the recent variant BA.2.86 restricts understanding of vaccine efficacy.
Conclusion:

Multiple booster vaccinations are beneficial for CLL patients, but ongoing immune suppression may necessitate additional protective strategies, highlighting the need for further research.

Original Source(s)

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

  • by Thomas Roberts, Grace Uwenedi, Rachel Bruton, Graham McIlroy, Sarah Damery, Panagiota Sylla, Nicola Logan, Sam Scott, May Lau, Ahmed Elzaidi, Siobhan Plass, Soumyajit Mallick, Katie Spencer, Christine Stephens, Christopher Bentley, Guy Pratt, Jianmin Zuo, Shankara Paneesha, Brian Willett, Paul Moss, Helen Parry

  • January 25, 2024

Related Content

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study

MIS-C: Diagnosis, Management, and Outcomes